Low affinity use-dependent NMDA receptor antagonists show promise for clinical development

Amino Acids

Volumn 19, Issue 1, 2000, Pages 151-155

  Palmer, G C ^a   Widzowski, D ^a  

^a Astra Zeneca R and D Boston   (United States)

Author keywords

Amino acids; Clinical status; Epilepsy; Head trauma; Low affinity use dependent antagonists; Neurodegeneration; NMDA; Stroke

Indexed keywords

AMANTADINE; BUDIPINE; DEXANABINOL; DEXTROMETHORPHAN; FELBAMATE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; REMACEMIDE;

ALZHEIMER DISEASE; AMNESIA; CLINICAL TRIAL; DRUG MECHANISM; DRUG SAFETY; DRUG SCREENING; EPILEPSY; HUMAN; HUNTINGTON CHOREA; NEUROLOGIC DISEASE; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; STROKE; TARDIVE DYSKINESIA; TREATMENT INDICATION;

CEREBROVASCULAR ACCIDENT; CRANIOCEREBRAL TRAUMA; EPILEPSY; EXCITATORY AMINO ACID ANTAGONISTS; HUMAN; NEURODEGENERATIVE DISEASES; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 0033796256     PISSN: 09394451     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007260070043     Document Type: Review

References (10)

1. Study of potency, kinetics of block and toxicity of NMDA-receptor antagonists using fura-2
2. Differences in degree of trapping of low-affinity uncompetitive N-methyl-D-aspartic acid receptor antagonists with similar kinetics of block
3. NR1 and NR2 subunit contributions to N-methyl-D-aspartate receptor channel blocker pharmacology
4. NPS 1506, a novel NMDA-receptor antagonist and neuroprotectant. Review of preclinical and clinical studies
5. The low affinity use dependent NMDA receptor antagonist AR-R 15896AR: An update of progress in stroke
6. Preclinical and clinical aspects of remacemide hydrochloride
7. Glutamate in CNS disorders as a target for drug development: An update
8. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist - A review of preclinical data
9. Regional variations in the pharmacology of NMDA receptor channel blockers: Implications for therapeutic potential
10. The NMDA receptor, NMDA-receptor antagonists and epilepsy therapy